ReviewFrontiers in immunology2025
Influences of metabolism and lipid homeostasis on regulatory vs. conventional T cells and implications for autoimmunity.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FASN-mediated metabolic reprogramming drives CD4Arthritis research & therapy · 2026Article
- Lipid Metabolism in Regulatory T Cells in Health and Disease.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Regulatory T cells are essential for suppressing an overactive immune system, especially concerning autoimmune disease, tumor growth, and inflammatory disease. This suppressive nature of regulatory T cells is largely due to their metabolic profiles determined by metabolic reprogramming upon activation and subsequent differentiation. As regulatory T cells tend to process and cycle energy differently from other T cell subsets, we are interested in what metabolic processes support regulatory T cell function. This review will consider how regulatory T cells compare with conventional T cells in terms of their participation in distinct metabolic pathways and how the presence of regulatory T cell-specific molecules influences proliferation and suppressive function. Additionally, this review will identify possible metabolic targets of regulatory T cells that could be targeted for development of autoimmune disease therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.